Could a sleep medication curb alcohol cravings?
NCT ID NCT07532252
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether daridorexant, a drug used for insomnia, can reduce alcohol cravings and drinking while improving sleep in people with alcohol use disorder and sleep problems. About 150 adults will receive either daridorexant or a placebo for several weeks. The goal is to see if targeting the brain's orexin system can help manage alcohol use in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daridorexant
What this could lead to
If it works, this could point toward a new treatment option for alcohol use disorder that also helps with sleep problems.
What could go wrong
This is an early phase 2 trial with only 150 people, so results may not apply to everyone. The drug may not reduce drinking or craving as hoped, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••